Crossmark

The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects

Crossref DOI link: https://doi.org/10.14283/jpad.2019.30

Published Print: 2019-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Edgar, Chris J.

Vradenburg, G.

Hassenstab, J.
License Information

Text and Data Mining valid from 2019-10-01

Text and Data Mining valid from 2019-10-01

Version of Record valid from 2024-09-25
More Information

This article is maintained by: Elsevier

Article Title: The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2019.30

Content Type: article

Copyright: Copyright © 2019 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS